Wissenschaftliche Literatur

Workshop on the validation of the Heparin-Induced-Platelet-Activation-Assay (HIPA). Annals of Haematology 1997, 74:

(97) Eichler P, Barthels K, Budde U, Haas S, Kroll H, Loreth M, Pachmann U, Pötzsch B, Salama A, Schabel A, Greinacher A.

Real time monitoring the efficacy of adjuvant therapy in breast cancer by quantifying the reduction of circulating tumor cells using the MAINTRAC analysis. Breast Cancer Research and Treatment 2000, 64:#402

(98) Pachmann K, Tolkmitt M, Mengel M, Rinas N, Dressel V, Lobodasch K, Tulusan AH, Pachmann U.

Laser scanning cytometry and magnet bead enrichment for rapid quantitative enumeration of minimal Numbers of tumor cells in peripheral blood and bone marrow in breast cancer patients. Journal of Clinical Oncology 2000, 18:Abstract# 541

(99) Pachmann K, Pachmann U.

Transfusion Medical Pharmacology: abcixmab selectively interferes with binding of human anti platelet auto- and alloantibodies to PIIb/IIIa as monitored by PSIFT and MAIPA. Vox Sanguinis 2000, 78 (suppl. 1), Poster#064

(100) Pachmann U, Jungwirth-Schill C, Stein EL

Antibodies against carbohydrate targets on GPIB/V/IX complex in Thrombocytopenic patients as detected by MAIPA. Vox Sanguinis 2000, 78 (suppl. 1), Poster#063

101) Jungwirth-Schill C, Pachmann U, Pachmann K.

HIPA Test: Improved sensitivity and specifity. Vox Sanguinis 2000, 78 (suppl. 1), Poster#054

(102) Pachmann U.

MAINTRAC Approach For Detection Of Circulating Tumour Cells: Sensitivity, Specificity, Reproducibility. Vox Sanguinis 2000, 78 (suppl. 1), Poster#615

(103) Pachmann K, Pachmann U.

Minimale residuale Tumorerkrankung bei soliden epithelialen Tumoren. Leserbrief: Neues automatisiertes Analyseverfahren. Deutsches Ärzteblatt 2000, 51/52:2630-2631 (Leserbrief)

(104) Pachmann K, Pachmann U.

LSC – Laser Scanning cytometry as an application for the detection of tumor cells in the peripheral blood. An experimental study. Onkologie 2000, 23(S7): Abstract#:0215

(105) Tilz GP, Pachmann K, Demel U.

Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia Cells as determined by in situ amplification. British Journal of Haematology 2001, 112:749-759

(106) Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreff M.

(107) Pachmann K, Lychatz S, Oblonczek G, Willen B

Tumorzell-Analyse mit kombinierter Magnetanreicherung, Laser-Scanning-Zytometrie und visueller Kontrolle. LABORWELT 2001, IV:23-26

(108) Pachmann K, Heiss P, Demel U, Tilz G.

Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC®). Clin Chem Lab Med 2001, 39:811-817

(109) Pachmann K, Tulusan AH, Lobodasch K, Dengler R, Pachmann M, Pachmann U.

Monitoring the efficacy of adjuvant therapy in breast cancer by quantifying circulating tumor cells using the MAINTRAC analysis (Laser scanning cytometry of magnetic bead enrichtment cells) 7th Congress of European Society for Analytical Cellular Pathology 2001, Abstract P6

Nachweis minimaler zirkulierender Tumorzellen mit Hilfe mikroflourimetrischer Analysen am Laser Scanning Cytometer (LSC). Innovationsforum 04.-05.September 2001, 18-19

(110) Pachmann K.

An approach to standardize the detection circulating tumor cells comparing different methods for analysis in peripheral blood and bone marrow. Onkologie 2003, 26(S5):191, P932

111) Pachmann K, Clement J, Höffken K, Pachmann U.

(112) Zimmermann I, Pachmann U, Seybold D, Mößmer G, Neumeier D.

Antibodies and HIT II- therapeutically relevant diagnostics. Haemostaseologie, 2004, 24:A59,P82

(113) Stein EL, Schulte M, Haendel M, Pachmann U.

Hereditary thrombophilic risk: There are no synergistic effects between six known risk factors- Apparent role of factor V Leiden in arterial thrombosis. Haemostaseologie 2004, 24:A71, P128

Influence of primary tumor chemotherapy in breast cancer on circulating tumor cells. Indications for massive cell release into circulations concurrent with tumor size reduction. Breast Cancer Research and Treatment 2004, 88:224, Abstract#6014

(114) Pachmann K, Camara O, Pachmann U.

Influence of Neoadjuvant Therapy in Breast Cancer on Circulating Tumor Cells. 95th Annual Meeting of the American Association for Cancer Research March 27-31, 2004, p.94, Abstract#LB-161

(115) Pachmann K, Camara O.

Human plasma increases the magnetic separation of tumor cells from peripheral blood leukocytes. 5th Colloquium DFG-Priority Program “Kolloidale magnetische Flüssigkeiten: Grundlagen Entwicklung und Anwendungen neuartiger Ferrofluide”. 27.-29.September 2004

(116) Schwalbe M, Hausschild F, Pachmann K, Clement JK.

Human Plasma Facilitates Enrichment of Circulating Epithelial Cells from Peripheral Blood. Onkologie 2004, 27(S3):142, P630

(117) Schwalbe M, Jörke C, Hausschild F, Höffken K, Pachmann K, Clement JH.

Synthesis of oligonucleotide-functionalized magnetic nanoparticles and study on their invitro cell uptakte. Appl. Organometal Chem 2004, 18:514-519

(118) Wagner K, Kautz A, Röder M, Schwalbe M, Pachmann K, Clement JH, Schnabelrauch M.

Neoadjuvant Chemotherapy for Breast Cancer Can Cause Release of Tumor Cells. Oncology News International, 2005, 03:29

(119) Pachmann K.

Quantitative monitoring of circulating epithelial cells for individal therapy control in lung and breast cancer during neoadjuvant treatment, surgery and adjuvant chemotherapy. Journal of Clinical Oncology 2005, 23(16S):36s, Abstract#631

(120) Pachmann K, Clement JH, Hoeffken K, Schneider CP, Lobodasch K, Camara O, Pachmann U.

Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005; 43:617-627

(121) Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, Höffken K.

Finding& Identifying Disseminated Tumor Cells as Biomarkers for Solid Cancers. Oncology Times 2005, XXVII(11):10-11

(122) Carlson RH.

K. Longtime Recirculating Tumor Cells in Breast Cancer Patients. Clinical Cancer Research 2005, 11:5657-5658

(123) Pachmann

Adjuvante homöopathische Therapie bei konventionell behandeltem Mammakarzinom, AHZ 2005, 250:127-133

(124) Hümmer H, Pachmann K, Pachmann U.

Increase in number of circulating disseminated ephitelial cells after sugery for non-small cell lung cancer monitoring by MAINTRAC is a predictor for relapse: A preliminary report. World Journal surgical Oncology 2005, 3:18

(125) Rolle A, Günzel R, Pachmann U, Willen B, Höffken K, Pachmann K.

Quantification of the Response of CirculatingEpithelial Cells (CEC) to Neodadjuvant Treatment of Breast Cancer: A New Tool for Therapy Monitoring. Breast Cancer Research 2005, 7:R975-R979

(126) Pachmann K, Camara O, Kavallaris A, Schneider U, Schünemann S, Höffken K.

Selective reduction of the interaction of magnetic nanoparticles with leucocytes and tumor cells by human plasma. Journal of Magnetism and Magnetic Materials 2005, 293:433-437

127) Schwalbe M, Jörke C, Buske N, Höffken K, Pachmann K, Clement JH.

Circulating tumor cells, tools for monitoring and targets for therapy. Journal of Clinical Oncology 2006, 24(18S):32, Abstract#617

(128) Pachmann K, Camara O, Lobodasch K, Dengler R, Runnebaum I, Hoeffken K, Pachmann U.

Influence of isotypes of disease-associated autoantibodies on the expression of natural autoantibody repertoires in humans. Immunology Letters 2006, 102:50-59

(129) Stahl D, Hoemberg M, Cassens U, Pachmann U, Sibrowski W.

The Carboxymethyl Dextran Shell is an Important Modulator of Magnetic Nanoparticle Uptake in Human Cells. Z Phys Chem 2006, 220:125-131

(130) Schwalbe M, Buske N, Vetterlein M, Höffken K, Pachmann K, Clement JH.

Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells. J Cancer Res Clin Oncol 2006, 132:287-292

(131) Clement JH, Schwalbe M, Buske N, Wagner K, Schnabelrauch M, Görnert P, Kliche KO, Pachmann K, Weitschies W, Höffken K.

Improvement of the separation of tumour cells from peripheral blood cells using magnetic nanoparticles. J Phys Condens Matter 2006, 18:1-12

(132) Schwalbe M, Pachmann K, Höffken K, Clement JH.

Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World Journal of Surgical Oncology 2006, 4:67

(133) Camara O, Kavallaris A, Nöschel H, Rengsberger M, Jörke C, Pachmann K.

Release of tumor cells during neoadjuvant therapie. Breast-Cancer-Research, Nov 1, 2006, Leserbrief zu: Breast Cancer Research 2006, 8:R60

(134) Pachmann K.

Longitudinal analysis of bone marrow infiltration in acute lymphatic leukemia during therapy: early detection of imminent relapse. Onkologie 2006, 29(s3): 78, P433

(135) Günther J, Waldau A, Hoeffken K, Pachmann K.

The hidden face of tumor treatment: tumor cell dissemination during treatment steps counteracts treatment success. Proc Amer Assoc Cancer Res, 2006, 47:Abstract#1968

(136) Pachmann K, Clement JH, Hoeffken K, Camara O, Schneider CP, Pachmann U.

Circulating tumor cells, tools for monitoring and targets for therapy. Onkologie 2006, 29(s3):129, Abstract#601

(137) Kohlhase A, Malarski N, Camara O, Krauspe S, Runnebaum I, Hoeffken K, Pachmann K.

Quantification of circulating tumour cells for monitoring of adjuvant therapy in breast cancer: An increase in cell number at completion of therapy is a predictor of early relapse. The Breast 2007, 16:211-218

(138) Lobodasch K, Dengler R, Fröhlich F, Rengsberger M, Schubert R, Pachmann U, Pachmann K.

Monitoring the Response of Circulating Epithelial Tumor Cells (CETC) to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse. J Clin Oncol 2008, 26 (8): 1208-1215

(139) Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Runnebaum I, Höffken K, Pachmann K.

Quantification of circulating tumor cells for monitoring of adjuvant therapy in breast cancer. An increase in cell number at completition of therapy may develop as an indicator of early relapse. J Cancer Res Clin Oncol 2008, 134:59-65

(140) Lobodasch K, Dengler, R, Fröhlich F, Rengsberger M, Schubert R, Pachmann U, Pachmann K.

The Relevance of Circulating Epithelial Tumour Cells (CETC) for Therapy Monitoring during Neoadjuvant (Primary Systemic) Chemotherapy in Breast Cancer. Annals of Oncology 2007, 18:1484-1492

(141) Camara O, Kavallaris A, Rengsberger M, Koch A, Schneider U, Egbe A, Untch M, Pachmann K.

A mathematical model for estimating the real risk of thrombosis. Hämostaseologie 2007, 27:A71, P139

(142) Pachmann U, Zimmermann I, Scharrer I.

Die Bedeutung zirkulierender epithelialer Tumorzellen (CETC) für die Therapieüberwachung in der neoadjuvanten und der adjuvanten Therapie des Mammakarzinoms. Senologie 2007, 4:A87, P129

(143) Pachmann K, Camara O, Kavallaris A, Lobodasch K, Rengsburger M, Koch A, Kroll T, Schünemann S, Pachmann U, Untch M, Höffken K.

Circulating epithelial tumor cells a new tool for therapy monitoring in breast cander: a more than tenfold increase in numbers during systemic therapy is highly predictive of relapse. Breast Cancer Research and Treatment 2007, 106 (Suppl 1):A110, P26

(144)Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll, T, Runnebaum I, HoeffkenK.

The initial response of circulating epithelial tumor cells to primary systemic chemotherapy in breast cancer is highly predictive for final tumor reduction an outcome. Breast Cancer Research and Treatment 2007, 106 (Suppl 1):A4019, P172

(145)Camara O, Kavallaris A, Rengsberger M, Koch A, Schneider U, Egbe A, Untch M, Pachmann K.

Targeting circulating epithelial tumor cells (CETC) to assess the effectivity and mode of action of new cytotoxic agents in breast cancer. Proceedings Supplement: Late-Breaking Abstracts 2008, #LB-183, p51-52

(146)Pachmann K, Stein EL, Rabenstein C, Clement HJ, Pachmann U.

The impact of systemic chemotherapy on circulating epithelial tumor cells (CETC) in breast cancer. J Clin Oncol 2008, 26 (suppl):578s (#11001)

(147)Pachmann K, Camara C, Hammer U, Joerke C, Krauspe S, Rabenstein C, Runnebaum IB, Hoeffken K.

The initial response of circulating epithelial tumor cells (CETC) during primary systemic therapy of breast cancer is predictive for early relapse. Ann Oncol 2008, 19(suppl5):136 (#24PD)

(148)Pachmann K, Camara O, Gajda M, Untch M, Hoeffken K.

Circulating Tumor Cells in Breast Cancer: Ficition or Reality? J Clin Oncol 2008, 26:3656-3657

(149) Pachmann K. In Reply. J Clin Oncol 2008, 26:3657-3658 to Cristofanilli M.

Monitoring circulating epithelial tumor cells (CETC) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors. Ann Oncol 2008, 19:2090-1

(150) Gajda M, Camara O, Oppel S, Kroll T, Jörke C, Krauspe S, Hammer U, Rabenstein C, Untch M, Runnebaum IB, Pachmann K.

Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. J Cancer Res Clin Oncol 2008, 135:643-7

(151) Camara O, Jörke C, Hammer U, Egbe A, Rabenstein C, Runnebaum IB, Hoeffken K, Pachmann K.

Behaviour and metastatic potential of her2/neu positive and her2/neu negative circulating epithelial tumor cells (CETC) during adjuvant systemic therapy in breast cancer. Cancer Res 2009, 69(Suppl):317s(#5030)

(152) Camara O, Hammer U, Gajda M, Kroll T, Krauspe S, Gellner A-K, Joerke C, Runnebaum IB, Hoeffken K, Pachmann K.

Metastatic potential of Her2/neu positive and Her2/neu negative circulating epithelial tumor cells (CETC) released during primary systemic chemotherapy. Cancer Res 2009, 69(Suppl):317s-318s (#5031)

(153) Pachmann K, Camara O, Gajda M, Rabenstein C, Pachmann U, Runnebaum IB.

Detection of tumor stem cells among circulating epithelial tumor cells (CETC) and relationship to therapy response. Cancer Res 2009, 69(Suppl):324s (#5053)

(154) Hekimian K, Stein EL, Pachmann U, Pachmann K.

Gauging the response of circulating epithelial tumor cells (CETC) an tumor stem cell subpopulation to therapy of early-stage. J Clin Oncol 2009, 27(S15):564 #11026

(155)Pachmann K, Camara O, Runnebaum IB, Hoeffken K.

Chemosensitivity Testing of Circulating Epithelial Cells (CETC) in Breast Cancer Patients and Correlation to Clinical Outcome. Cancer Res 2009, 69(Suppl):606s (#2044)

(156) Pachmann K, Stein EL, Schill E, Pachmann U.

Changing Therapy as a Consequence of the Behaviour of CETC during Adjuvant Trastuzumab Treatment in Patients with Her2/Neu Positive Breast Cancer. Cancer Res 2009, 69(Suppl):612s (#2088)

(157) Hammer U, Camara O, Hekimian K, Gellner AK, Runnebaum IB, Pachmann K.

Circulating Epithelial Cells as a Tool for Monitoring Treatment Success of Primary Chemotherapy with Simultaneous or Sequential and without Trastuzumab. Cancer Res 2009, 69(Suppl):651s (#3016)

(158) Camara O, Kroll T, Oppel S, Runnebaum IB, Pachmann K.

Circulating Epithelial Tumor Cell (CETC) Monitoring during SERM and Aromatase Inhibitor Treatment for Early Detection of Patients Resistant to Tamoxifen. Cancer Res 2009, 69(Suppl):808s (#5129)

(159) Pachmann K, Camara O, Rabenstein C, Winzer H, Runnebaum IB.